Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO

被引:13
|
作者
Murayama, T [1 ]
Imoto, S [1 ]
Natazuka, T [1 ]
Chihara, K [1 ]
Matsui, T [1 ]
机构
[1] Kobe Univ, Sch Med, Dept Med, Div 3,Chuo Ku, Kobe, Hyogo 650, Japan
关键词
acute myelogenous leukemia; G-CSF; GM-CSF; M-CSF; proliferation; SCF; TPO;
D O I
10.1016/S0145-2126(98)00042-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, many cytokines have been defined and some of them used clinically. In hematological malignancies, cytokines, including granulocyte colony-stimulating factor (G-CSF), have been widely used for leukopenia after chemotherapy. However, in acute myelogenous leukemia (AML), some leukemic cells may be induced to proliferate by these cytokines and they must be used with care. In this study, we have investigated cell reactivity and proliferation with G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CMF), macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF) and thrombopoietin (TPO) in cases of AML. We have also investigated the reactivity of some myeloid leukemia cell lines to TPO. G-CSF, GM-CSF, M-CSF, SCF and TPO caused proliferation of leukemic cells in 25%, 58.3%, 8.3%, 21.1% and 0% of cases, respectively. Because of this result, the use of G-CSF in AML should be regarded as potentially hazardous. TPO did not cause proliferation of leukemic cells in any case of AML, or in cell lines except MO7E, which is a megakaryocytic cell line. This result suggests that TPO might cause proliferation of some megakaryocytic leukemia cells. We cannot conclude that TPO does not cause proliferation of other AML cells, as the number of cases was small and it has been reported elsewhere that leukemia cells may proliferate when exposed to TPO in 50% of AML cases. Reactivity of AML cells to TPO is an important factor when deciding the indications of TPO in AML and myelodysplastic syndrome. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:557 / 560
页数:4
相关论文
共 50 条
  • [31] G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis
    Cornish, Ann L.
    Campbell, Ian K.
    McKenzie, Brent S.
    Chatfield, Simon
    Wicks, Ian P.
    NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (10) : 554 - 559
  • [32] IMMUNOPHENOTYPIC CHARACTERIZATION OF HUMAN PERITONEAL AND ALVEOLAR MACROPHAGES AND OF HUMAN BLOOD MONOCYTES DIFFERENTIATED IN THE PRESENCE OF EITHER GM-CSF OR M-CSF OR A COMBINATION OF GM-CSF M-CSF
    EISCHEN, A
    VINCENT, F
    LOUIS, B
    SCHMITTGOGUEL, M
    BOHBOT, A
    BERGERAT, JP
    OBERLING, F
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1992, 34 (06): : 421 - 434
  • [33] RESPONSE OF LEUKEMIC-CELLS TO THE SEQUENTIAL COMBINATION OF GM-CSF AND G-CSF
    INOUE, C
    MURATE, T
    HOTTA, T
    SAITO, H
    INTERNATIONAL JOURNAL OF CELL CLONING, 1990, 8 (01): : 54 - 62
  • [34] Immune Evasion of G-CSF and GM-CSF in Lung Cancer
    Park, Yeonhee
    Chung, Chaeuk
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (01) : 22 - 30
  • [35] The potential role of GM-CSF and G-CSF in infectious diseases
    Deresinski, SC
    Kemper, CA
    INFECTIONS IN MEDICINE, 1998, 15 (12) : 856 - +
  • [36] G-CSF AND GM-CSF - BIOLOGY AND CLINICAL-APPLICATION
    GOLDE, DW
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (03): : 319 - 319
  • [37] THE USE OF GM-CSF AND G-CSF IN THE TREATMENT OF ACUTE LEUKEMIAS
    HAROUSSEAU, JL
    WU, DP
    LEUKEMIA & LYMPHOMA, 1995, 18 (5-6) : 405 - 412
  • [38] DIFFERENCES IN THE NEUTROPHIL PRIMING EFFECTS OF G-CSF AND GM-CSF
    TREWEEKE, AT
    AZIZ, KA
    ZUZEL, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 : 66 - 66
  • [39] G-CSF、GM-CSF的临床应用现状
    童英
    杨琳
    苏文英
    基础医学与临床, 2000, (02) : 5 - 8
  • [40] G-CSF AND GM-CSF IN RESPIRATORY-DISTRESS SYNDROME
    YURDAKOK, M
    GURAKAN, B
    ERGIN, H
    KIRAZLI, S
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (02) : 155 - 156